(Reuters) – Biogen Inc said on Wednesday it would terminate a post-approval study of its first Alzheimer’s drug, Aduhelm, and discontinue all commercialization for the …
By Svea Herbst-Bayliss NEW YORK (Reuters) – Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen <BIIB.O> shareholders elect Susan Langer to replace …
(Reuters) – The U.S. Food and Drug Administration on Friday approved Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug lecanemab for the treatment of early …
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) – Japan’s Eisai Co plans to seek full approval of its experimental Alzheimer’s drug lecanemab in …
(Reuters) – Mathai Mammen, a former executive at drugmaker Johnson & Johnson, has emerged as a top candidate to head Biogen as chief executive officer, …
BOSTON – Pharmaceutical company Biogen Inc. (Biogen), based in Cambridge, Massachusetts, has agreed to pay $900 million to resolve allegations that it violated the False …
(Reuters) – Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure …
By Deena Beasley – Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s …
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen …